格隆汇1月13日丨九安医疗(002432.SZ)公布，截至2026年1月12日，公司股份回购期限已届满。回购期 限内，公司通过股票回购专用证券账户以集中竞价交易方式累计回购公司股份数11,229,901股，占目前 公司总股本的2.42%，最高成交价为41.60元/股，最低成交价为39.598元/股，支付总金额为人民币 451,950,498.72元（不含交易费用），回购期限自公司董事会审议通过最终回购股份方案之日起不超过3 个月。本次回购符合相关法律法规的要求，符合公司既定的回购方案。至此，本次股份回购已实施完 毕。 ...

证券代码：002432 证券简称：九安医疗 公告编号：2026-003 天津九安医疗电子股份有限公司 关于回购期限届满暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年10月13日召 开第六届董事会第二十七次会议，逐项审议并通过了《关于公司回购股份方案的 议案》，同意公司拟以自有资金不低于3亿元人民币（含）且不超过6亿元人民币 （含）且回购价格不超过人民币53.5元/股（含）回购公司股份。本次回购股份全 部用于维护公司价值及股东权益，实施期限为自公司董事会审议通过最终回购股 份方案之日起不超过3个月。具体详见2025年10月14日在《证券时报》、巨潮资 讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案暨取得股票回购专 项贷款承诺函的公告》（公告编号：2025-075）。 截至2026年1月12日，公司股份回购期限已届满，本次股份回购已实施完毕。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第9号 —回购股份》等相关规定，现将相关情况公告如下： ...

九安医疗公告称，截至2026年1月12日，公司股份回购期限届满，本次股份回购实施完毕。回购期内， 公司以集中竞价方式累计回购1122.99万股，占总股本2.42%，最高成交价41.60元/股，最低39.598元/ 股，支付总金额4.52亿元。实际回购情况与方案无差异，未对公司经营等产生重大影响。此外，董事、 副总经理王湧因股票期权激励计划行权，持股增加1.88万股。回购股份存放专户，12个月后可出售，若 未售完将注销。 ...

Core Viewpoint - The article discusses the performance of the Chinese stock market in 2025, highlighting a "slow bull" trend with significant gains in A-shares and Hong Kong stocks, particularly noting the impressive performance of the ChiNext index with nearly 50% growth [2]. Group 1: Market Performance - By December 31, 2025, the average increase in A-shares was 38.15%, with 572 stocks doubling in value. In comparison, the "924 market" from 2024 saw an average increase of 87.84%, with 1586 stocks doubling [2]. - The number of "broken net" stocks decreased from 836 in the previous "924 market" to 303, representing only 5.54% of all A-shares, indicating a market recovery [3]. Group 2: Broken Net Stocks - The article categorizes broken net stocks into five groups: broken net + performance stocks, broken net + repurchase stocks, broken net stocks + state-owned holdings, broken net + high dividend stocks, and broken net + low price stocks [4]. - Among the 303 broken net stocks, only 15 were identified as performance stocks with significant revenue growth and profit increases of over 50% [4]. Group 3: Repurchase Stocks - Of the 303 broken net stocks, 72 companies engaged in stock repurchases, with 29 companies repurchasing over 100 million yuan. This indicates management's belief that their stock prices are undervalued [6][7]. - The top three companies by repurchase amount in 2025 were Jiuan Medical (925 million yuan), China State Construction (887 million yuan), and Youngor (693 million yuan) [7]. Group 4: High Dividend Stocks - There are 22 broken net stocks with a dividend yield of over 5%, enhancing their investment appeal due to potential capital appreciation and stable dividend income [9]. - Among these, Jizhong Energy had a net asset ratio of 0.99 and a dividend yield of 11.15%, despite a significant drop in revenue and profit [9]. Group 5: State-Owned Holdings - The "national team" held 95 broken net stocks in the third quarter, with significant investments in Agricultural Bank of China, Bank of China, and Industrial and Commercial Bank of China, indicating a focus on stabilizing these sectors [11][12]. - The national team increased its holdings in 17 broken net stocks, with six being newly added in the third quarter [11]. Group 6: Low Price Stocks - There are 34 broken net stocks priced below 3 yuan, with only 7 showing positive revenue and profit growth, indicating that many may not have strong underlying asset values [14].

Core Viewpoint - The medical device industry is currently in a challenging phase, with "endurance" being a key theme. Leading companies are proactively adjusting their strategies, including product structure changes and international expansion, as seen with Mindray Medical [1][3]. Group 1: Company Strategies - Mindray Medical is increasing the proportion of in vitro diagnostic (IVD) products in its overall revenue while decreasing the share of life information and support products and medical imaging products [1]. - The company aims to shift from traditional medical equipment sales to a more sustainable consumable-driven business model through IVD products [1]. - As of mid-2025, Mindray's overseas revenue share rose to 49.77%, up from 39.59% in mid-2022, indicating a strong push for international market penetration [3]. Group 2: Industry Challenges - The IVD sector is facing intense price competition and regulatory challenges domestically, making it a difficult environment for growth [3]. - The overall revenue for the A-share IVD sector declined by 14.5% year-on-year in the first three quarters of 2025, with net profit down 26.4%, marking three consecutive years of decline [8]. Group 3: Company Performance - Ji'an Medical, another key player, reported a net profit of 16.03 billion yuan in 2022, showcasing the potential of the IVD sector despite the current downturn [3]. - Ji'an Medical's overseas revenue accounted for 85.47% of total revenue by mid-2025, highlighting its successful international expansion compared to peers [8]. - Despite a 48.89% drop in total revenue to 1.069 billion yuan in the first three quarters of 2025, Ji'an Medical's net profit increased by 16.11% to 1.589 billion yuan, supported by over 1.1 billion yuan in investment income [7]. Group 4: Investment Strategies - Ji'an Medical is focusing on stable cash management and increasing investments in venture capital and private equity rather than pursuing aggressive mergers and acquisitions [7]. - The company has diversified its investment portfolio, including stakes in companies like Xiaomi and NIO, and plans to use up to 17 billion yuan for wealth management [10]. - Ji'an Medical's stock price has shown resilience, with a 9.17% increase in 2024 and a slight decline of 1.33% in 2025, outperforming industry peers [7]. Group 5: Future Outlook - Ji'an Medical's management believes that the current market valuation does not reflect the company's true value, prompting share buyback initiatives to stabilize stock prices [10]. - The company has received FDA pre-market notifications for new IVD products, which could enhance its competitive edge in the market [11]. - The overall recovery of the industry is crucial for Ji'an Medical's main business, but its dual strategy of combining medical devices with investment could provide a viable path forward during challenging times [11].

（文章来源：证券日报） 证券日报网讯 1月6日，九安医疗在互动平台回答投资者提问时表示，截至2025年12月31日，公司最新 股东人数约6.85万户。 ...

证券代码：002432 证券简称：九安医疗 公告编号：2026-002 天津九安医疗电子股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 经营范围：一般项目：第一类医疗器械生产；第一类医疗器械销售；第一类 医疗设备租赁；第二类医疗器械销售；第二类医疗设备租赁；机械设备研发；机 械设备销售；电子产品销售；仪器仪表制造；仪器仪表销售；可穿戴智能设备制 造；可穿戴智能设备销售；智能车载设备制造；智能车载设备销售；信息技术咨 询服务；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；软 件开发；软件销售；软件外包服务；互联网数据服务；健康咨询服务（不含诊疗 服务）；货物进出口；技术进出口；日用百货销售；家用电器销售；智能家庭消 天津九安医疗电子股份有限公司（以下简称"公司"）分别于2025年11月28 日、2025年12月15日召开第六届董事会第二十九次会议、2025年第四次临时股东 大会，审议通过了《关于变更注册资本、新增经营范围暨修订<公司章程>的议 案》。具体内容详见2025年11月29日刊登于公司指定信息披露媒 ...

格隆汇1月6日丨九安医疗(002432.SZ)公布，截至2025年12月31日，公司通过股份回购专用证券账户以 集中竞价方式累计回购公司股份数11,229,901股，占公司目前总股本的2.42%，最高成交价为41.60元/ 股，最低成交价为39.598元/股，支付的总金额为人民币451,950,498.72元（不含交易费用）。本次回购 符合相关法律法规的要求，符合既定的回购股份方案。 ...

证券代码：002432 证券简称：九安医疗 公告编号：2026-001 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年10月13日召 开了第六届董事会第二十七次会议，审议并通过了《关于公司回购股份方案的议 案》。本次回购资金来源为公司自有资金及回购专项贷资金，回购的资金总额不 低于3亿元人民币（含）且不超过6亿元人民币（含），回购股份的价格为不超过 人民币53.5元/股（含），具体回购数量以回购期限届满时实际回购的股份数量为 准。具体回购方案详见公司2025年10月14日在《证券时报》和巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于回购公司股份方案暨取得股票回购专 项贷款承诺函的公告》（公告编号：2025-075）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号—回购股份》等相关规定，公司在回购期间应当在每个月的前3个交易日内公 告截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 一、回购股份的具体情况 1、公司未在下列期间内回购公司股票： 天津九安医疗电子股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信 ...

每经头条（nbdtoutiao）——原指导价34.99万的宝马裸车价22.5万元，多家车企还补贴购置税！2026开 年车市火爆，销售从早到晚忙到没空吃饭 每经AI快讯，九安医疗1月6日晚间发布公告称，截至2025年12月31日，公司通过股份回购专用证券账 户以集中竞价方式累计回购公司股份数约1123万股，占公司目前总股本的2.42%，最高成交价为41.6元/ 股，最低成交价为约39.60元/股，支付的总金额为人民币约4.52亿元。 （记者 王瀚黎） ...